Serum glial-derived neurotrophic factor and nerve growth factor levels in patients with COVID-19

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0001-8791-5331en_US
dc.authorscopusid57256923300en_US
dc.authorwosid-en_US
dc.contributor.authorTürkeri, Ö. N.
dc.contributor.authorÖzgeriş, F. B.
dc.contributor.authorKoçak Ö.F.
dc.contributor.authorKurt N.
dc.contributor.authorYüce N.
dc.contributor.authorBakan N.
dc.contributor.authorParlak E.
dc.date.accessioned2024-01-24T13:41:33Z
dc.date.available2024-01-24T13:41:33Z
dc.date.issued2023en_US
dc.departmentMeslek Yüksekokulları, Sağlık Hizmetleri Meslek Yüksekokulu, Eczane Hizmetleri Bölümü
dc.description.abstractIntroduction and objective: The new type of coronavirus (COVID-19) causes high fever, fatigue, cough, respiratory distress, diarrhea, headache in some patients, cerebrovascular diseases, unconsciousness, encephalopathy, encephalitis, peripheral nervous system damage, etc. It is a viral respiratory disease that manifests itself with neurological findings. In our study, glial-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) levels of neurotrophic factors (NF), which ensure the survival, growth, maturation and differentiation of neurons were investigated in COVID-19 patients, including their relationship with the severity of the disease. Materials and methods: Out of a total of 70 participants, 20 participants are in the healthy control group (CG) and 50 participants are in the group of patients with COVID-19 according to PCR test (uncomplicated group [NCG], moderately severe group [MG], severe group [SG]). Serum NGF and GDNF levels in all groups were evaluated spectrophotometrically using ELISA kits. The results were compared both between the patient groups and between the patient and healthy control groups. Results: Serum NGF concentration was significantly higher in the MG group than in the NCG and the SG group (P = 0.042). No statistically significant difference was found in serum GDNF levels in COVID-19 patients and CG. Conclusion: There was no difference in serum NGF and serum GDNF levels in COVID-19 patients compared to the healthy control group.en_US
dc.identifier.citationTürkeri, O. N., Özgeriş, F. B., Koçak Ö.F., Kurt N., Yüce N., Bakan N., & Parlak E. (2023). Serum glial-derived neurotrophic factor and nerve growth factor levels in patients with COVID-19. Ceska a Slovenska Neurologie a Neurochirurgie, 86(2), 128-133. doi: 10.48095/cccsnn2022128en_US
dc.identifier.doi10.48095/cccsnn2022128
dc.identifier.endpage133en_US
dc.identifier.issn1210-7859
dc.identifier.issn1802-4041
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85162752594
dc.identifier.startpage128en_US
dc.identifier.urihttps://doi.org/10.48095/cccsnn2022128
dc.identifier.urihttps://hdl.handle.net/20.500.12428/5401
dc.identifier.volume86en_US
dc.identifier.wosWOS:000995956700001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorTürkeri, Özge Nur
dc.language.isoen
dc.publisherCzech Medical Association J.E. Purkyneen_US
dc.relation.ispartofCeska a Slovenska Neurologie a Neurochirurgieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCoronavirusen_US
dc.subjectCOVID-19en_US
dc.subjectGlial-derived neurotrophic factoren_US
dc.subjectNerve growth factoren_US
dc.titleSerum glial-derived neurotrophic factor and nerve growth factor levels in patients with COVID-19
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ozge_Nur_Turkeri_Makale.pdf
Boyut:
194.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Araştırma Makalesi
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Sağlık Hizmetleri Meslek Yüksekokulu Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu